Drug Patents owned by Viiv Hlthcare

1. Drug name - APRETUDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8410103 VIIV HLTHCARE (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Apr, 2026

(3 years from now)

US10927129 VIIV HLTHCARE N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
Apr, 2026

(3 years from now)

CN101346376A VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Jul, 2011

(11 years ago)

CN101212903B VIIV HLTHCARE Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

CN101212903A VIIV HLTHCARE Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1852434A1 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP1852434B1 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP1852434A4 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP2527007B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3372281A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3187225B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3045206A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3284520A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3284520B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3187225A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3372281B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3045206B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2527007A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117B8 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117A4 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2465580A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2465580B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1950212B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP1950212A4 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP1950212A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11224597 VIIV HLTHCARE Pharmaceutical compositions Sep, 2031

(8 years from now)

Drugs and Companies using CABOTEGRAVIR ingredient

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
600MG/3ML (200MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

2. Drug name - CABENUVA KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080551 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2023

(6 months from now)

US7125879 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2025

(2 years from now)

US8410103 VIIV HLTHCARE (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Apr, 2026

(3 years from now)

US10927129 VIIV HLTHCARE N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
Apr, 2026

(3 years from now)

CN101346376A VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Jul, 2011

(11 years ago)

CN101056673A VIIV HLTHCARE 4-[[4-[[4-(2-Cyanovinyl)-2,6-Dimethylphenyl]Amino]-2-Pyrimidyl]Amino] Benzonitrile Hydrochloride
Jun, 2015

(7 years ago)

CN101816658A VIIV HLTHCARE Pyramine Derivatives For Inhibiting Hiv
Aug, 2022

(a month ago)

CN101816658B VIIV HLTHCARE Hiv Inhibiting Pyrimidines Derivatives
Aug, 2022

(a month ago)

CN1541215A VIIV HLTHCARE Hiv Inhibiting Pyrimidine Derivatives
Aug, 2022

(a month ago)

CN100509801C VIIV HLTHCARE Hiv Inhibiting Pyrimidines Derivatives
Aug, 2022

(a month ago)

CN101060844A VIIV HLTHCARE Composition Of Rt Inhibitor And Nnrti Containing Pyrimidine
Sep, 2024

(1 year, 10 months from now)

CN101068597A VIIV HLTHCARE Fumaric Acid Salt Of 4-((4-((4-(2-Cyanovinyl)-2, 6-) Dimethylphenyl Amido)-2- Pyrimidyl) Amido) Benzonitrile
Sep, 2024

(1 year, 10 months from now)

CN101068597B VIIV HLTHCARE 4 - ((4 - ((4 - (2) -2, 6 -) Dimethylphenyl Amido) -2 - Pyrimidyl) Amido) Benzonitrile
Sep, 2024

(1 year, 10 months from now)

CN101060844B VIIV HLTHCARE Combinations Of A Pyrimidine Containing Nnrti With Rt Inhibitors
Sep, 2024

(1 year, 10 months from now)

CN101212903A VIIV HLTHCARE Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

CN101212903B VIIV HLTHCARE Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

CN102245182A VIIV HLTHCARE Synthesis Of Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediate
Dec, 2029

(7 years from now)

CN102245182B VIIV HLTHCARE Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediates For Synthesis
Dec, 2029

(7 years from now)

CN102791129B VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

CN102791129A VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

CN105311033B VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

CN105311033A VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

IN222987B VIIV HLTHCARE A Pyrimidine Compound Of Formula (I)
Aug, 2022

(a month ago)

IN200400265P1 VIIV HLTHCARE Hiv Inhibiting Pyrimidines Derivatives
Aug, 2022

(a month ago)

IN373756B VIIV HLTHCARE Process For The Preparation Of Carbamoylpyrid One Hiv Integrase Inhibitors
Dec, 2029

(7 years from now)

IN201838011858A VIIV HLTHCARE Process For The Preparation Of Carbamoylpyridone Hiv Integrase Inhibitors
Dec, 2029

(7 years from now)

IN201201811P2 VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

IN301970B VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

EP1663240A1 VIIV HLTHCARE Combinations Of A Pyrimidine Containing Nnrti With Rt Inhibitors
Jul, 2020

(2 years ago)

EP1663240B1 VIIV HLTHCARE Combinations Of A Pyrimidine Containing Nnrti With Rt Inhibitors
Jul, 2020

(2 years ago)

EP1632232A1 VIIV HLTHCARE Salt Of 4[[4-[[4-(2-Cyanoethenyl)-2,6-Dimethylphenyl]Amino]-2-Pyrimidinyl]Amino]Benzonitrile
Feb, 2022

(7 months ago)

EP1632232B1 VIIV HLTHCARE Salt Of 4[[4-[[4-(2-Cyanoethenyl)-2,6-Dimethylphenyl]Amino]-2-Pyrimidinyl]Amino]Benzonitrile
Feb, 2022

(7 months ago)

EP2298761B1 VIIV HLTHCARE Hiv Inhibiting Pyrimidines Derivatives
Aug, 2022

(a month ago)

EP2298761A1 VIIV HLTHCARE Hiv Inhibiting Pyrimidines Derivatives
Aug, 2022

(a month ago)

EP3808743B1 VIIV HLTHCARE Hiv Replication Inhibiting Pyrimidines
Aug, 2022

(a month ago)

EP3808743A1 VIIV HLTHCARE Hiv Replication Inhibiting Pyrimidines
Aug, 2022

(a month ago)

EP1789139A1 VIIV HLTHCARE Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile
Sep, 2025

(2 years from now)

EP1789139B1 VIIV HLTHCARE Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile
Sep, 2025

(2 years from now)

EP1852434A1 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP1852434B1 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP1852434A4 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP2527007B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3372281A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3187225B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3045206A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3284520A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3284520B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3187225A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3372281B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3045206B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2527007A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117B8 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117A4 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2465580A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2465580B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1950212B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP1950212A4 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP1950212A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP1419152A1 VIIV HLTHCARE Hiv Inhibiting Pyrimidines Derivatives
Nov, 2026

(4 years from now)

EP1419152B1 VIIV HLTHCARE Hiv Inhibiting Pyrimidines Derivatives
Nov, 2026

(4 years from now)

EP2376080A1 VIIV HLTHCARE Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates
Dec, 2029

(7 years from now)

EP2376080B1 VIIV HLTHCARE Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates
Dec, 2029

(7 years from now)

EP2376080A4 VIIV HLTHCARE Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates
Dec, 2029

(7 years from now)

EP3127542A1 VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

EP2531027A1 VIIV HLTHCARE Therapeutic Combination Comprising Dolutegravir, Abacavir And Lamivudine
Jan, 2031

(8 years from now)

EP3127542B1 VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

EP2531027A4 VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

EP2531027B1 VIIV HLTHCARE Therapeutic Combination Comprising Dolutegravir, Abacavir And Lamivudine
Jan, 2031

(8 years from now)

EP2932970A1 VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

EP2932970B1 VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11224597 VIIV HLTHCARE Pharmaceutical compositions Sep, 2031

(8 years from now)

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

Treatment: Treatment of hiv infection in adults

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
400MG/2ML (200MG/ML);600MG/2ML (300MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
600MG/3ML (200MG/ML);900MG/3ML (300MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

3. Drug name - DOVATO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(4 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(7 years from now)

CN101346376A VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Jul, 2011

(11 years ago)

CN101212903A VIIV HLTHCARE Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

CN101212903B VIIV HLTHCARE Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

CN102245182A VIIV HLTHCARE Synthesis Of Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediate
Dec, 2029

(7 years from now)

CN102245182B VIIV HLTHCARE Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediates For Synthesis
Dec, 2029

(7 years from now)

IN373756B VIIV HLTHCARE Process For The Preparation Of Carbamoylpyrid One Hiv Integrase Inhibitors
Dec, 2029

(7 years from now)

IN201838011858A VIIV HLTHCARE Process For The Preparation Of Carbamoylpyridone Hiv Integrase Inhibitors
Dec, 2029

(7 years from now)

EP1852434A1 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP1852434B1 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP1852434A4 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP2527007B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3372281A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3187225B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3045206A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3284520A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3284520B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3187225A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3372281B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3045206B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2527007A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117B8 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117A4 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2465580A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2465580B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1950212B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP1950212A4 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP1950212A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP2376080A1 VIIV HLTHCARE Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates
Dec, 2029

(7 years from now)

EP2376080B1 VIIV HLTHCARE Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates
Dec, 2029

(7 years from now)

EP2376080A4 VIIV HLTHCARE Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates
Dec, 2029

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11234985 VIIV HLTHCARE Antiviral therapy Jan, 2031

(8 years from now)

Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE;300MG TABLET;ORAL Prescription

4. Drug name - JULUCA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080551 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2023

(6 months from now)

US7125879 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2025

(2 years from now)

US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(4 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(7 years from now)

US10426780 VIIV HLTHCARE Antiviral therapy
Jan, 2031

(8 years from now)

CN101346376A VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Jul, 2011

(11 years ago)

CN101056673A VIIV HLTHCARE 4-[[4-[[4-(2-Cyanovinyl)-2,6-Dimethylphenyl]Amino]-2-Pyrimidyl]Amino] Benzonitrile Hydrochloride
Jun, 2015

(7 years ago)

CN101816658A VIIV HLTHCARE Pyramine Derivatives For Inhibiting Hiv
Aug, 2022

(a month ago)

CN101816658B VIIV HLTHCARE Hiv Inhibiting Pyrimidines Derivatives
Aug, 2022

(a month ago)

CN1541215A VIIV HLTHCARE Hiv Inhibiting Pyrimidine Derivatives
Aug, 2022

(a month ago)

CN100509801C VIIV HLTHCARE Hiv Inhibiting Pyrimidines Derivatives
Aug, 2022

(a month ago)

CN101060844A VIIV HLTHCARE Composition Of Rt Inhibitor And Nnrti Containing Pyrimidine
Sep, 2024

(1 year, 10 months from now)

CN101068597A VIIV HLTHCARE Fumaric Acid Salt Of 4-((4-((4-(2-Cyanovinyl)-2, 6-) Dimethylphenyl Amido)-2- Pyrimidyl) Amido) Benzonitrile
Sep, 2024

(1 year, 10 months from now)

CN101068597B VIIV HLTHCARE 4 - ((4 - ((4 - (2) -2, 6 -) Dimethylphenyl Amido) -2 - Pyrimidyl) Amido) Benzonitrile
Sep, 2024

(1 year, 10 months from now)

CN101060844B VIIV HLTHCARE Combinations Of A Pyrimidine Containing Nnrti With Rt Inhibitors
Sep, 2024

(1 year, 10 months from now)

CN101212903A VIIV HLTHCARE Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

CN101212903B VIIV HLTHCARE Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

CN102245182A VIIV HLTHCARE Synthesis Of Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediate
Dec, 2029

(7 years from now)

CN102245182B VIIV HLTHCARE Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediates For Synthesis
Dec, 2029

(7 years from now)

CN102791129B VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

CN102791129A VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

CN105311033B VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

CN105311033A VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

IN222987B VIIV HLTHCARE A Pyrimidine Compound Of Formula (I)
Aug, 2022

(a month ago)

IN200400265P1 VIIV HLTHCARE Hiv Inhibiting Pyrimidines Derivatives
Aug, 2022

(a month ago)

IN373756B VIIV HLTHCARE Process For The Preparation Of Carbamoylpyrid One Hiv Integrase Inhibitors
Dec, 2029

(7 years from now)

IN201838011858A VIIV HLTHCARE Process For The Preparation Of Carbamoylpyridone Hiv Integrase Inhibitors
Dec, 2029

(7 years from now)

IN201201811P2 VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

IN301970B VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

EP1663240A1 VIIV HLTHCARE Combinations Of A Pyrimidine Containing Nnrti With Rt Inhibitors
Jul, 2020

(2 years ago)

EP1663240B1 VIIV HLTHCARE Combinations Of A Pyrimidine Containing Nnrti With Rt Inhibitors
Jul, 2020

(2 years ago)

EP1632232A1 VIIV HLTHCARE Salt Of 4[[4-[[4-(2-Cyanoethenyl)-2,6-Dimethylphenyl]Amino]-2-Pyrimidinyl]Amino]Benzonitrile
Feb, 2022

(7 months ago)

EP1632232B1 VIIV HLTHCARE Salt Of 4[[4-[[4-(2-Cyanoethenyl)-2,6-Dimethylphenyl]Amino]-2-Pyrimidinyl]Amino]Benzonitrile
Feb, 2022

(7 months ago)

EP2298761B1 VIIV HLTHCARE Hiv Inhibiting Pyrimidines Derivatives
Aug, 2022

(a month ago)

EP2298761A1 VIIV HLTHCARE Hiv Inhibiting Pyrimidines Derivatives
Aug, 2022

(a month ago)

EP3808743B1 VIIV HLTHCARE Hiv Replication Inhibiting Pyrimidines
Aug, 2022

(a month ago)

EP3808743A1 VIIV HLTHCARE Hiv Replication Inhibiting Pyrimidines
Aug, 2022

(a month ago)

EP1789139A1 VIIV HLTHCARE Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile
Sep, 2025

(2 years from now)

EP1789139B1 VIIV HLTHCARE Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile
Sep, 2025

(2 years from now)

EP1852434A1 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP1852434B1 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP1852434A4 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP2527007B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3372281A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3187225B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3045206A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3284520A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3284520B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3187225A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3372281B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3045206B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2527007A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117B8 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117A4 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2465580A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2465580B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1950212B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP1950212A4 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP1950212A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP1419152A1 VIIV HLTHCARE Hiv Inhibiting Pyrimidines Derivatives
Nov, 2026

(4 years from now)

EP1419152B1 VIIV HLTHCARE Hiv Inhibiting Pyrimidines Derivatives
Nov, 2026

(4 years from now)

EP2376080A1 VIIV HLTHCARE Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates
Dec, 2029

(7 years from now)

EP2376080B1 VIIV HLTHCARE Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates
Dec, 2029

(7 years from now)

EP2376080A4 VIIV HLTHCARE Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates
Dec, 2029

(7 years from now)

EP3127542A1 VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

EP2531027A1 VIIV HLTHCARE Therapeutic Combination Comprising Dolutegravir, Abacavir And Lamivudine
Jan, 2031

(8 years from now)

EP3127542B1 VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

EP2531027A4 VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

EP2531027B1 VIIV HLTHCARE Therapeutic Combination Comprising Dolutegravir, Abacavir And Lamivudine
Jan, 2031

(8 years from now)

EP2932970A1 VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

EP2932970B1 VIIV HLTHCARE Antiviral Therapy
Jan, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE;EQ 25MG BASE TABLET;ORAL Prescription

5. Drug name - RUKOBIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8461333 VIIV HLTHCARE Salts of prodrugs of piperazine and substituted piperidine antiviral agents
Feb, 2025

(2 years from now)

US7745625 VIIV HLTHCARE Prodrugs of piperazine and substituted piperidine antiviral agents
Nov, 2027

(5 years from now)

CN101941990B VIIV HLTHCARE Piperazine And Prodrug Of Substituted Piperidine Antiviral Drug
Mar, 2025

(2 years from now)

CN1953985B VIIV HLTHCARE Piperazine And Prodrug Of Substituted Piperidine Antiviral Drug
Mar, 2025

(2 years from now)

CN1953985A VIIV HLTHCARE Prodrugs Of Piperazine And Substituted Piperidine Antiviral Agents
Mar, 2025

(2 years from now)

CN101941990A VIIV HLTHCARE Pyrazine Antiviral Drug And Prodrug Of Piperazine And Substituted
Mar, 2025

(2 years from now)

IN254948B VIIV HLTHCARE A Compound Of Formula I
Mar, 2025

(2 years from now)

IN200605355P1 VIIV HLTHCARE Prodrugs Of Piperazine And Substituted Piperidine Antiviral Agents
Mar, 2025

(2 years from now)

EP1725569B1 VIIV HLTHCARE Prodrugs Of Piperazine And Substituted Piperidine Antiviral Agents
Mar, 2025

(2 years from now)

EP1725569A1 VIIV HLTHCARE Prodrugs Of Piperazine And Substituted Piperidine Antiviral Agents
Mar, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168615 VIIV HLTHCARE Prodrugs of piperazine and substituted piperidine antiviral agents Feb, 2025

(2 years from now)

Drugs and Companies using FOSTEMSAVIR TROMETHAMINE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 600MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

6. Drug name - SELZENTRY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7368460 VIIV HLTHCARE Tropane derivatives useful in therapy Nov, 2022

(a month from now)

US7368460

(Pediatric)

VIIV HLTHCARE Tropane derivatives useful in therapy May, 2023

(7 months from now)

Drugs and Companies using MARAVIROC ingredient

Treatment: Method of treating patients infected with ccr5-tropic hiv-1

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
20MG/ML SOLUTION;ORAL Prescription

7. Drug name - TIVICAY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(4 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(7 years from now)

CN101346376A VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Jul, 2011

(11 years ago)

CN101212903A VIIV HLTHCARE Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

CN101212903B VIIV HLTHCARE Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

CN102245182A VIIV HLTHCARE Synthesis Of Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediate
Dec, 2029

(7 years from now)

CN102245182B VIIV HLTHCARE Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediates For Synthesis
Dec, 2029

(7 years from now)

IN373756B VIIV HLTHCARE Process For The Preparation Of Carbamoylpyrid One Hiv Integrase Inhibitors
Dec, 2029

(7 years from now)

IN201838011858A VIIV HLTHCARE Process For The Preparation Of Carbamoylpyridone Hiv Integrase Inhibitors
Dec, 2029

(7 years from now)

EP1852434A1 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP1852434B1 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP1852434A4 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP2527007B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3372281A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3187225B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3045206A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3284520A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3284520B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3187225A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3372281B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3045206B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2527007A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117B8 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117A4 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2465580A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2465580B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1950212B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP1950212A4 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP1950212A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP2376080A1 VIIV HLTHCARE Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates
Dec, 2029

(7 years from now)

EP2376080B1 VIIV HLTHCARE Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates
Dec, 2029

(7 years from now)

EP2376080A4 VIIV HLTHCARE Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates
Dec, 2029

(7 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE TABLET;ORAL Prescription
EQ 25MG BASE TABLET;ORAL Prescription
EQ 50MG BASE TABLET;ORAL Prescription

8. Drug name - TIVICAY PD

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(4 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(7 years from now)

CN101346376A VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Jul, 2011

(11 years ago)

CN101212903A VIIV HLTHCARE Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

CN101212903B VIIV HLTHCARE Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

CN102245182A VIIV HLTHCARE Synthesis Of Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediate
Dec, 2029

(7 years from now)

CN102245182B VIIV HLTHCARE Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediates For Synthesis
Dec, 2029

(7 years from now)

IN373756B VIIV HLTHCARE Process For The Preparation Of Carbamoylpyrid One Hiv Integrase Inhibitors
Dec, 2029

(7 years from now)

IN201838011858A VIIV HLTHCARE Process For The Preparation Of Carbamoylpyridone Hiv Integrase Inhibitors
Dec, 2029

(7 years from now)

EP1852434A1 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP1852434B1 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP1852434A4 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP2527007B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3372281A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3187225B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3045206A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3284520A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3284520B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3187225A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3372281B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3045206B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2527007A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117B8 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117A4 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2465580A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2465580B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1950212B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP1950212A4 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP1950212A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP2376080A1 VIIV HLTHCARE Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates
Dec, 2029

(7 years from now)

EP2376080B1 VIIV HLTHCARE Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates
Dec, 2029

(7 years from now)

EP2376080A4 VIIV HLTHCARE Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates
Dec, 2029

(7 years from now)

Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient

Treatment: NA

Dosage: TABLET, FOR SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE TABLET, FOR SUSPENSION;ORAL Prescription

9. Drug name - TRIUMEQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(4 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(7 years from now)

CN101346376A VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Jul, 2011

(11 years ago)

CN101212903A VIIV HLTHCARE Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

CN101212903B VIIV HLTHCARE Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

CN102245182A VIIV HLTHCARE Synthesis Of Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediate
Dec, 2029

(7 years from now)

CN102245182B VIIV HLTHCARE Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediates For Synthesis
Dec, 2029

(7 years from now)

IN373756B VIIV HLTHCARE Process For The Preparation Of Carbamoylpyrid One Hiv Integrase Inhibitors
Dec, 2029

(7 years from now)

IN201838011858A VIIV HLTHCARE Process For The Preparation Of Carbamoylpyridone Hiv Integrase Inhibitors
Dec, 2029

(7 years from now)

EP1852434A1 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP1852434B1 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP1852434A4 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP2527007B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3372281A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3187225B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3045206A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3284520A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3284520B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3187225A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3372281B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3045206B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2527007A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117B8 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117A4 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2465580A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2465580B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1950212B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP1950212A4 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP1950212A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP2376080A1 VIIV HLTHCARE Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates
Dec, 2029

(7 years from now)

EP2376080B1 VIIV HLTHCARE Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates
Dec, 2029

(7 years from now)

EP2376080A4 VIIV HLTHCARE Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates
Dec, 2029

(7 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 600MG BASE;EQ 50MG BASE;300MG TABLET;ORAL Prescription

10. Drug name - VOCABRIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10927129 VIIV HLTHCARE N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
Apr, 2026

(3 years from now)

US8410103 VIIV HLTHCARE (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Apr, 2026

(3 years from now)

CN101346376A VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Jul, 2011

(11 years ago)

CN101212903B VIIV HLTHCARE Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

CN101212903A VIIV HLTHCARE Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1852434A1 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP1852434B1 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP1852434A4 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP2527007B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3372281A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3187225B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3045206A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3284520A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3284520B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3187225A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3372281B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3045206B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2527007A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117B8 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117A4 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2465580A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2465580B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1950212B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP1950212A4 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP1950212A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 30MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.